CLEARWATER, Fla.--(BUSINESS WIRE)--Bovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma®, a patented new surgical product, today announced that it has added two Senior Surgical Device Specialists to its direct sales force. They will be responsible for the J-Plasma® roll-out and growth in their assigned territories.
“We continue to execute on our strategy of building a highly-credentialed direct sales force to accelerate the adoption of our J-Plasma product,” said Robert L. Gershon, Chief Executive Officer. “These two new Senior Surgical Device Specialists bring our direct sales force to 15 professionals, and come to Bovie Medical with proven track records in sales, training and new product roll-outs.”
Brad Boklage joined Bovie as a Senior Surgical Device Specialist, effective November 10, 2014. Most recently, Brad served as Region Manager-Product Development at Lexion Management, a surgical device manufacturer. Previous to that, Brad had a successful sales and marketing career in consumer products, at TEAM Enterprises and Kraft Foods.
Benjamin Kirsch came on board December 1, 2014 as a Senior Surgical Specialist. Brad Joins Bovie with 10 years of medical sales experience, most recently serving as Regional Sales Manager at AtriCure, a medical device company. Prior to that, Benjamin was Senior Cardiovascular Representative at CryoLife, Inc., and Cardiovascular Sales Specialist at Novartis Pharmaceuticals.
The Senior Surgical Device Specialists have been awarded stock options to purchase an aggregate of 20,000 shares of Bovie common stock exercisable at the closing price as of today, December 17, 2014. The options shall vest and be exercisable in four equal annual installments beginning on the first anniversary of the effective date.
Both Brad and Benjamin will report to Todd Hormby, Vice President, Sales, at Bovie Medical.
In addition, Bovie today announced the appointment of Brian S. Kunst as Vice President of Clinical and Regulatory Affairs, effective November 10, 2014. Mr. Kunst has more than 25 years of regulatory experience, holding positions including Director, Regulatory Affairs at Abbot Vascular Inc. and Vice President, Regulatory Affairs and Quality Assurance at Angiodynamics Inc. He will report to Senior Vice President Moshe Citronowicz.
“We are pleased to welcome Brian on board as a member of the Bovie team. His decades of experience in managing regulatory and clinical affairs will be an important asset as we continue our growth in both our core business and the J-Plasma roll-out,” Mr. Gershon said.
Mr. Kunst has been awarded stock options to purchase an aggregate of 30,000 shares of Bovie common stock exercisable at the closing price as of today, December 17, 2014. The options shall vest and be exercisable in four equal annual installments beginning on the first anniversary of the effective date.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal thermal spread, and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com.
Cautionary Statement on Forward-Looking Statements
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Reports on Forms 10-K/A and 10-Qs for the year ended December 31, 2013 and the quarters ended March 31, 2014, June 30, 2014 and September 30, 2014. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.